Radiopharm Theranostics surges 85.68% amid market gains
Radiopharm Theranostics Ltd experienced a significant price increase of 85.68% in pre-market trading, as the stock crossed above its 5-day SMA. This surge comes amid broader market strength, with the Nasdaq-100 up 0.56% and the S&P 500 up 0.48%. The stock's impressive movement suggests a strong interest from investors, potentially indicating a shift in market sentiment towards the biotech sector.
The positive movement aligns with the overall market conditions, suggesting that investor confidence is rising. The stock's performance could be attributed to sector rotation as investors seek opportunities in companies like Radiopharm Theranostics, which are positioned for growth. This trend reflects a broader interest in innovative healthcare solutions, particularly in the context of recent advancements in the biotech field.
As the market continues to show strength, Radiopharm Theranostics Ltd's upward trajectory may attract further attention from investors. The stock's ability to maintain momentum will be crucial in the coming days, especially as market conditions evolve and new developments in the biotech sector emerge.
Trade with 70% Backtested Accuracy
Analyst Views on RADX
About RADX
About the author
Radiopharm Initiates Phase 1 Trial of RAD 402 for Prostate Cancer
- Trial Launch: Radiopharm Theranostics announced that the first patient has been dosed in the Phase 1 clinical trial of RAD 402, which aims to evaluate safety and preliminary efficacy for prostate cancer, marking a significant advancement in the company's innovative oncology treatments.
- Targeting Mechanism Innovation: RAD 402 is a monoclonal antibody targeting KLK3, radiolabelled with Terbium 161, with preclinical data showing strong tumor targeting in mouse xenografts while exhibiting minimal bone marrow uptake and expected hepatic clearance, indicating its potential for clinical application.
- Dose Escalation Design: The Phase 1 trial employs a dose escalation design to determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D), laying the groundwork for future clinical expansion and reflecting the company's commitment to this program and its patients.
- Partner Support: Radiopharm CEO Riccardo Canevari expressed gratitude to TerThera and Cyclotek for their support in supplying Tb161, radiolabelling, and distributing RAD 402, highlighting the importance of collaboration in advancing innovative therapeutic solutions.
Radiopharm's First Radiotherapeutic Agent Enters Clinical Trials
- Clinical Trial Launch: Radiopharm Theranostics announced the first dosing of its radiotherapeutic agent 177Lu-BetaBart (RV-01) in a First-In-Human Phase 1/2a clinical trial, marking a significant milestone that is expected to provide new treatment options for patients with advanced solid tumors.
- Mechanism of Action: 177Lu-BetaBart is a monoclonal antibody targeting B7-H3, which has shown potential for tumor shrinkage and prolonged survival in preclinical studies, particularly demonstrating good targeting in various tumor types including prostate, pancreatic, and breast cancers.
- Trial Scale: The clinical trial aims to enroll 61 eligible participants across multiple cancer types, including castrate-resistant prostate cancer and small cell lung cancer, with the goal of assessing the safety and pharmacokinetics of 177Lu-BetaBart.
- Strategic Implications: This study not only showcases Radiopharm's innovative capabilities in the development of radiopharmaceuticals but also positions the company for a significant competitive advantage in the highly competitive oncology market, potentially driving future commercial growth.
Radiopharm Theranostics Reports Interim Clinical Trial Results and Financial Update
- Clinical Trial Results: In the Phase 2b trial of RAD 101 for patients with brain metastases, 92% of evaluable participants met the primary endpoint of MRI concordance, and if confirmed, this will trigger preparations for a multi-center Phase 3 registrational trial.
- Strong Financial Position: As of December 31, 2025, Radiopharm reported cash and cash equivalents of approximately $34.52 million, up from $29.12 million at year-end, providing a runway into 2027 to advance high-value radiotherapeutic programs.
- Drug Development Progress: RAD 202 and RAD 204 have both received recommendations from the Data Safety Monitoring Committee to escalate dosing, with RAD 202 moving to 75mCi and RAD 204 showing favorable safety and tumor uptake in PD-L1-driven cancers.
- Future Outlook: Radiopharm aims to deliver meaningful data across multiple programs in 2026, focusing on expanding treatment and diagnostic options for solid tumor patients while creating long-term value for all stakeholders.
Benzinga Market Update: Carnival, Caterpillar, Meta Among Stocks as Markets See Slight Increases
Market Performance: The stock market experienced moderate gains due to softer inflation data and stable unemployment, with the Dow Jones and S&P 500 rising, while the Nasdaq rebounded, indicating investor confidence in a potential rate cut by the Federal Reserve in 2026.
Earnings Highlights: Micron Technology exceeded expectations and raised its guidance, boosting AI-related semiconductor stocks, while Nike's cautious outlook on global demand, especially in China, led to a decline in its shares.
Sector Resilience: Transportation and travel sectors showed strength, with FedEx reporting solid quarterly results and Carnival Corporation reinstating its dividend and forecasting strong demand for 2026, despite ongoing macroeconomic uncertainties.
Investor Sentiment: Reports indicated a shift in focus from hype around AI to companies demonstrating clear profitability, with notable bearish sentiments surrounding stocks like Meta and Novo Nordisk, which faced challenges in their respective markets.
Dow Declines by 50 Points; US Employment Increases by 64,000 in November
U.S. Stock Market Performance: U.S. stocks traded mostly lower, with the Dow Jones falling over 50 points, while the S&P 500 and NASDAQ also experienced slight declines. Information technology shares rose by 0.1%, but energy stocks dropped by 1.8%.
Job Market Update: The U.S. economy added 64,000 jobs in November, slightly above expectations but still below healthy job creation levels. The unemployment rate rose to 4.6%, marking the highest since September 2021.
Equities Trading Highlights: SRx Health Solutions saw a significant increase in shares by 117% after an acquisition announcement, while Zynex Inc shares plummeted 59% due to entering Chapter 11 restructuring.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices like Japan's Nikkei and Spain's IBEX 35. In commodities, oil prices fell by 1.9%, while gold saw a slight increase.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
Radiopharm Initiates Phase 1 Trial of RAD 402 for Prostate Cancer
- Trial Launch: Radiopharm Theranostics announced that the first patient has been dosed in the Phase 1 clinical trial of RAD 402, which aims to evaluate safety and preliminary efficacy for prostate cancer, marking a significant advancement in the company's innovative oncology treatments.
- Targeting Mechanism Innovation: RAD 402 is a monoclonal antibody targeting KLK3, radiolabelled with Terbium 161, with preclinical data showing strong tumor targeting in mouse xenografts while exhibiting minimal bone marrow uptake and expected hepatic clearance, indicating its potential for clinical application.
- Dose Escalation Design: The Phase 1 trial employs a dose escalation design to determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D), laying the groundwork for future clinical expansion and reflecting the company's commitment to this program and its patients.
- Partner Support: Radiopharm CEO Riccardo Canevari expressed gratitude to TerThera and Cyclotek for their support in supplying Tb161, radiolabelling, and distributing RAD 402, highlighting the importance of collaboration in advancing innovative therapeutic solutions.
Radiopharm's First Radiotherapeutic Agent Enters Clinical Trials
- Clinical Trial Launch: Radiopharm Theranostics announced the first dosing of its radiotherapeutic agent 177Lu-BetaBart (RV-01) in a First-In-Human Phase 1/2a clinical trial, marking a significant milestone that is expected to provide new treatment options for patients with advanced solid tumors.
- Mechanism of Action: 177Lu-BetaBart is a monoclonal antibody targeting B7-H3, which has shown potential for tumor shrinkage and prolonged survival in preclinical studies, particularly demonstrating good targeting in various tumor types including prostate, pancreatic, and breast cancers.
- Trial Scale: The clinical trial aims to enroll 61 eligible participants across multiple cancer types, including castrate-resistant prostate cancer and small cell lung cancer, with the goal of assessing the safety and pharmacokinetics of 177Lu-BetaBart.
- Strategic Implications: This study not only showcases Radiopharm's innovative capabilities in the development of radiopharmaceuticals but also positions the company for a significant competitive advantage in the highly competitive oncology market, potentially driving future commercial growth.
Radiopharm Theranostics Reports Interim Clinical Trial Results and Financial Update
- Clinical Trial Results: In the Phase 2b trial of RAD 101 for patients with brain metastases, 92% of evaluable participants met the primary endpoint of MRI concordance, and if confirmed, this will trigger preparations for a multi-center Phase 3 registrational trial.
- Strong Financial Position: As of December 31, 2025, Radiopharm reported cash and cash equivalents of approximately $34.52 million, up from $29.12 million at year-end, providing a runway into 2027 to advance high-value radiotherapeutic programs.
- Drug Development Progress: RAD 202 and RAD 204 have both received recommendations from the Data Safety Monitoring Committee to escalate dosing, with RAD 202 moving to 75mCi and RAD 204 showing favorable safety and tumor uptake in PD-L1-driven cancers.
- Future Outlook: Radiopharm aims to deliver meaningful data across multiple programs in 2026, focusing on expanding treatment and diagnostic options for solid tumor patients while creating long-term value for all stakeholders.
Benzinga Market Update: Carnival, Caterpillar, Meta Among Stocks as Markets See Slight Increases
Market Performance: The stock market experienced moderate gains due to softer inflation data and stable unemployment, with the Dow Jones and S&P 500 rising, while the Nasdaq rebounded, indicating investor confidence in a potential rate cut by the Federal Reserve in 2026.
Earnings Highlights: Micron Technology exceeded expectations and raised its guidance, boosting AI-related semiconductor stocks, while Nike's cautious outlook on global demand, especially in China, led to a decline in its shares.
Sector Resilience: Transportation and travel sectors showed strength, with FedEx reporting solid quarterly results and Carnival Corporation reinstating its dividend and forecasting strong demand for 2026, despite ongoing macroeconomic uncertainties.
Investor Sentiment: Reports indicated a shift in focus from hype around AI to companies demonstrating clear profitability, with notable bearish sentiments surrounding stocks like Meta and Novo Nordisk, which faced challenges in their respective markets.
Dow Declines by 50 Points; US Employment Increases by 64,000 in November
U.S. Stock Market Performance: U.S. stocks traded mostly lower, with the Dow Jones falling over 50 points, while the S&P 500 and NASDAQ also experienced slight declines. Information technology shares rose by 0.1%, but energy stocks dropped by 1.8%.
Job Market Update: The U.S. economy added 64,000 jobs in November, slightly above expectations but still below healthy job creation levels. The unemployment rate rose to 4.6%, marking the highest since September 2021.
Equities Trading Highlights: SRx Health Solutions saw a significant increase in shares by 117% after an acquisition announcement, while Zynex Inc shares plummeted 59% due to entering Chapter 11 restructuring.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices like Japan's Nikkei and Spain's IBEX 35. In commodities, oil prices fell by 1.9%, while gold saw a slight increase.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
